FY2024 Earnings Estimate for InflaRx Issued By HC Wainwright

InflaRx (NASDAQ:IFRX) – HC Wainwright cut their FY2024 earnings per share estimates for shares of InflaRx in a research note issued to investors on Monday, November 11th. HC Wainwright analyst E. White now expects that the company will post earnings of ($1.05) per share for the year, down from their previous forecast of ($0.97). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2024 earnings at ($0.31) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.13) EPS.

InflaRx Trading Down 3.9 %

NASDAQ:IFRX opened at $1.95 on Thursday. The firm has a fifty day simple moving average of $1.54 and a 200 day simple moving average of $1.52. InflaRx has a 1-year low of $1.16 and a 1-year high of $2.44. The stock has a market capitalization of $114.82 million, a PE ratio of -1.81 and a beta of 1.57.

Institutional Inflows and Outflows

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC increased its holdings in shares of InflaRx (NASDAQ:IFRX) by 2.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 704,987 shares of the company’s stock after purchasing an additional 16,383 shares during the period. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 as of its most recent filing with the SEC. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.